七生物标志物预后特征用于美国癌症联合委员会第8版I-IIA期皮肤黑色素瘤辅助治疗试验招募的高危患者识别
研究在439例连续I-IIA期皮肤黑色素瘤患者中,评估基于免疫组化的七生物标志物特征对无病生存、黑色素瘤特异性生存和总生存的预后价值。结果显示该特征可独立于AJCC分期识别高危患者,且联合临床病理因素后预测模型性能优于单独临床病理因素。
要点
- 七生物标志物特征将25.1%(110/439)的I-IIA期患者划为高危。
- 高危患者无病生存、黑色素瘤特异性生存和总生存均显著差于低危患者(P<0.001)。
- 联合七生物标志物风险分类的模型预测各结局的AUC均高于单独临床病理模型。
核心结论
- 在AJCC早期皮肤黑色素瘤患者中,七生物标志物特征可独立于AJCC分类可靠预测黑色素瘤相关结局,并作为临床病理和人口学因素的有价值补充。
研究设计与样本
- 使用前瞻性收集的全组织切片,在连续I-IIA期患者(N=439)中评估既往验证过的基于免疫组化的七生物标志物特征。
- 主要终点为黑色素瘤特异性生存(MSS),同时评估无病生存(DFS)和总生存(OS)。
主要发现
- 七生物标志物特征将25.1%(110/439)的患者划为高危,其中IA期13.3%(43/323)、IB期53.2%(42/79)、IIA期67.6%(25/37)。
- Kaplan-Meier分析显示高危患者DFS、MSS和OS均显著差于低危患者(P<0.001)。
- 多变量Cox回归模型包含关键临床病理和人口学因素时,七生物标志物特征数据可独立预测所研究终点。
- 含七生物标志物风险分类加临床病理/人口学协变量的模型在预测所有研究结局上均大幅优于仅含临床病理/人口学变量的模型:DFS的AUC为74.1% vs 68.4%,MSS为81.5% vs 71.2%,OS为80.9% vs 73.0%;绝对差异分别为5.7%、10.3%和7.9%,均有利于含七生物标志物风险分类的模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Many patients with resected American Joint Committee on Cancer (AJCC) early-stage cutaneous melanoma nonetheless die of melanoma; additional risk stratification approaches are needed. PATIENTS AND METHODS: Using prospectively-collected whole-tissue sections, we assessed in consecutive stage I-IIA patients (N = 439), a previously-validated, immunohistochemistry-based, 7-biomarker signature to prognosticate disease-free survival (DFS), melanoma-specific survival (MSS; primary end-point) and overall survival (OS), independent of AJCC classification. RESULTS: Seven-marker signature testing designated 25.1% of patients (110/439) as high-risk (stage IA, 13.3% [43/323], IB, 53.2% [42/79], and IIA, 67.6% [25/37]). A Kaplan-Meier analysis demonstrated high-risk patients to have significantly worse DFS, MSS and OS versus low-risk counterparts (P < 0.001). In multivariable Cox regression modelling also including key clinicopathological/demographic factors, 7-marker signature data independently prognosticated the studied end-points. Models with the 7-marker signature risk category plus clinicopathological/demographic covariates substantially outperformed models with clinicopathological/demographic variables alone in predicting all studied outcomes (areas under the receiver operator characteristic curve 74.1% versus 68.4% for DFS, 81.5% versus 71.2% for MSS, 80.9% versus 73.0% for OS; absolute differences 5.7%, 10.3% and 7.9%, respectively, favouring 7-marker signature risk category-containing models). CONCLUSION: In patients with AJCC early-stage disease, the 7-marker signature reliably prognosticates melanoma-related outcomes, independent of AJCC classification, and provides a valuable complement to clinicopathological/demographic factors.
引用
- Meyer S, Buser L, Haferkamp S, et al. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma. Eur J Cancer. 2023. PMID: 36753835. doi:10.1016/j.ejca.2023.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。